Aytu BioScience

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Aytu BioScience reports robust Q3 performance, eyes growth through innovation

Aytu BioScience delivered strong financial results in Q3 2024, with notable revenue and margin improvements. The company's strategic focus on specialty pharmaceuticals and operational efficiency bodes well for future growth. While challenges like supply chain disruptions exist, Aytu is poised for continued success through innovation and market opportunities.

Aytu BioScience reports robust earnings, focuses on growth strategies

Aytu BioScience demonstrated strong financial performance with improved EBITDA and strategic repositioning
While facing challenges in certain portfolio revenues, the company is focused on growth opportunities
Strategic initiatives like the RxConnect program and product expansion are key strengths
Addressing market challenges and seizing growth opportunities will be crucial for future success

Aytu BioPharma reports first-ever positive net income in Q1 2025

Aytu BioPharma delivered a strong performance in Q1 2025, achieving positive net income, sustained profitability, and operational efficiency amidst market challenges.
The company's focus on optimizing operations, reducing expenses, and pursuing growth opportunities positions it well for future revenue expansion and market competitiveness.
While facing challenges in a dynamic market environment, Aytu BioPharma has opportunities to leverage its strengths in key portfolios and strategic initiatives for sustained growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023. The Company has scheduled a conference call that same day, Tuesday, November 14, 2023, at 4:30 pm ET, to review the results.

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD Product Margins DENVER, CO / ACCESSWIRE / October 26, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS). This approval enables the transfer of manufacturing of Cotempla to the Company's third-party manufacturer and follows a similar achievement for Adzenys XR- ODT® ("Adzenys") which received PAS approval in April 2023.

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://investors.aytubio.com/ or https://wsw.com/webcast/lytham9/aytu/2072440.

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

ESS Tech

Sirius XM Holdings Inc

Scienjoy Holding Corp

What do you consider the best penny stocks? Are they the ones exploding higher within a single session?

Best Penny Stocks? 4 Hot Stocks With News This Week

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call.

Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript

Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023 Company to host conference call today at 4:30pm ET ENGLEWOOD, CO / ACCESSWIRE / September 27, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fourth quarter and fiscal year ended June 30, 2023. Q4 2023 Commercial Highlights (3 months ending June 30, 2023) Total net revenue was $30.7 million, an increase of 12% from the $27.4 million in net revenue in the year-ago quarter and the highest in company history.

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.

Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023

ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main Event XVI Conference, being held on October 3-5, 2023, at Luxe Sunset Boulevard Hotel in Los Angeles. Management will present on Wednesday, October 4th at 10:00am PT.

Aytu BioPharma to Present at LD Micro Main Event XVI Conference

After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHD ENGLEWOOD, CO and GIVATAYIM, ISRAEL / ACCESSWIRE / July 31, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, and Medomie Pharma Ltd, a privately owned pharmaceutical company focused on distributing and selling innovative branded medicines, biosimilars and niche generic products for patients in Israel and the Palestinian Authority, today announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT® and Cotempla XR-ODT® product lines. Medomie will seek local regulatory approvals and marketing authorizations for both Adzenys and Cotempla.

Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority

Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Improve ADHD Product Margins by an Estimated Fifteen Percent ENGLEWOOD, CO / ACCESSWIRE / July 10, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, has submitted the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS) to the U.S. Food & Drug Administration (FDA). If approved, the PAS would enable Aytu to transfer the production of Cotempla to the Company's third-party manufacturer.

Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

ENGLEWOOD, CO / ACCESSWIRE / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced Joshua Disbrow, Aytu's Chief Executive Officer, will participate in a company discussion and host one-on-one meetings with investors at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, taking place virtually from June 20-22, 2023. Mr. Disbrow will participate in a discussion about the company with Naz Rahman, CFA, Senior Biotechnology Analyst at Maxim Group on June 21, 2023 at 3:00pm ET.

Aytu to Participate in the Maxim Group Virtual Healthcare Conference

Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term Loan Through January 2025 Maturity Date ENGLEWOOD, CO / ACCESSWIRE / June 13, 2023 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of (i) 1,743,695 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of its common stock ("Pre-Funded Warrants"), and (ii) accompanying Tranche A and Tranche B warrants (the "Common Warrants") to purchase 4,347,824 shares of its common stock, priced at-the-market under the rules of the Nasdaq Capital Market (the "Offering"). Gross proceeds, before deducting placement agent fees and other offering expenses, were approximately $4.0 million.

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term Loan Through January 2025 Maturity Date ENGLEWOOD, CO / ACCESSWIRE / June 9, 2023 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of (i) 1,743,695 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of its common stock ("Pre-Funded Warrants"), and (ii) accompanying Tranche A and Tranche B warrants (the "Common Warrants") to purchase 4,347,824 shares of its common stock priced at-the-market under Nasdaq rules (the "Offering"). Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.0 million (assuming no exercise of the Common Warrants).

Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Naz Rahman - Maxim Group, LLC Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call.

Aytu BioPharma, Inc. (AYTU) Q3 2023 Earnings Call Transcript

Aytu Biopharma (NASDAQ: AYTU ) just posted results for its fiscal third quarter. Aytu reported a loss per share of $1.93.

AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates

Total prescriptions increased 32% compared to Q3 2022 to highest level in Company history Company to host conference call today at 4:30pm ET ENGLEWOOD, CO / ACCESSWIRE / May 11, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended March 31, 2023. Q3 2023 Commercial Highlights (3 months ending March 31, 2023) Total net revenue was $22.7 million, a decrease of 6% from the $24.2 million in net revenue in the year-ago quarter.

Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results

ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its third quarter fiscal year 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023. The Company has scheduled a conference call that same day, Thursday, May 11, 2023, at 4:30 pm ET, to review the results.

Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023

ENGLEWOOD, CO / ACCESSWIRE / May 1, 2023 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an agreement with AMT Manufacturing Solutions, LLC ("AMTMS"), a newly established, full service Contract Manufacturing Organization ("CMO"), to sublease 22,909 square feet of Aytu's Grand Prairie, TX manufacturing facility. This sublease represents over 30% of the Company's FDA and DEA-approved pharmaceutical manufacturing facility.

Aytu BioPharma Subleases a Portion of Its Manufacturing Facility

U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023 Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Improve ADHD Product Margins by an Estimated 15% ENGLEWOOD, CO / ACCESSWIRE / April 27, 2023 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, received U.S. Food & Drug Administration ("FDA") approval of the Adzenys XR-ODT® ("Adzenys") Prior Approval Supplement ("PAS"). This approval enables the transfer of manufacturing of Adzenys to the Company's third-party manufacturer.

Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer

Aytu BioPharma Inc. (AYTU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2023 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Vernon Bernardino - H.C. Wainwright Operator Greetings.

Aytu BioPharma, Inc. (AYTU) Q2 2023 Earnings Call Transcript

Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call Today at 5:00pm ET ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended December 31, 2022. Q2 2023 Commercial Highlights (3 months ending December 31, 2022) Total net revenue was $26.3 million, an increase of 14% over the $23.1 million in net revenue in the year ago quarter.

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023

ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for the quarter ended December 31, 2022, after the market close today, Tuesday, February 21, 2023. The Company has also scheduled a conference call for today, Tuesday, February 21, 2023, at 5:00 pm ET, to review the results.

Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023

ENGLEWOOD, CO / ACCESSWIRE / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the delayed filing of its Form 10-Q for its second quarter fiscal year 2023, ended December 31, 2022 to allow for additional assessment and management review time on an accounting matter. The matter is related to the accounting for warrants issued in previous financings and we believe will not affect assets, cash and cash equivalents, revenue, cost of goods sold, operating expenses, loss from operations or adjusted EBITDA.

Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results

ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its second quarter fiscal year 2023, ended December 31, 2022, after the market close on Tuesday, February 14, 2023. The Company has scheduled a conference call that same day, Tuesday, February 14, 2023, at 4:30 pm ET, to review the results.

News for Aytu BioScience Stock (AYTU)